000212457 001__ 212457
000212457 005__ 20240229154907.0
000212457 0247_ $$2doi$$a10.1001/jamanetworkopen.2022.52387
000212457 0247_ $$2pmid$$apmid:36692879
000212457 0247_ $$2altmetric$$aaltmetric:141747247
000212457 037__ $$aDKFZ-2023-00174
000212457 041__ $$aEnglish
000212457 082__ $$a610
000212457 1001_ $$0P:(DE-He78)104fae0755c89365b7ae32238b3f1f52$$aStocker, Hannah$$b0$$eFirst author$$udkfz
000212457 245__ $$aAssociation of Kidney Function With Development of Alzheimer Disease and Other Dementias and Dementia-Related Blood Biomarkers.
000212457 260__ $$aChicago, Ill.$$bAmerican Medical Association$$c2023
000212457 3367_ $$2DRIVER$$aarticle
000212457 3367_ $$2DataCite$$aOutput Types/Journal article
000212457 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1674717927_19106
000212457 3367_ $$2BibTeX$$aARTICLE
000212457 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000212457 3367_ $$00$$2EndNote$$aJournal Article
000212457 500__ $$a#EA:C070#LA:C070#
000212457 520__ $$aPrevious research has suggested an association of kidney function with risk of Alzheimer disease (AD) or other dementias and dementia-related blood biomarkers, but a distinct association remains unclear.To evaluate the association of kidney function with risk of diagnosis of incident AD or dementia within 17 years and with the blood biomarkers neurofilament light (NfL), phosphorylated tau181 (p-tau181), and glial fibrillary acidic protein (GFAP).In this prospective, population-based cohort study and nested case-control study, 9940 participants in Germany were enrolled between 2000 and 2002 by their general practitioners and followed up for up to 17 years. Participants were included if information on dementia status and creatinine/cystatin C measurements were available. A subsample of participants additionally had measurements of NfL, p-tau181, and GFAP obtained from blood samples. Statistical analysis was performed from January 3 to November 25, 2022.Impaired kidney function, based on estimated glomerular filtration rate less than 60 mL/min/1.73 m2 according to the 2021 Chronic Kidney Disease Epidemiology Collaboration creatinine-cystatin C equation.All-cause dementia, AD, and vascular dementia diagnosis, as well as log-transformed levels of NfL, p-tau181, and GFAP in blood.Of 6256 participants (3402 women [54.4%]; mean [SD] age at baseline, 61.7 [6.6] years), 510 received an all-cause dementia diagnosis within 17 years of baseline. The dementia-related blood biomarker nested case-control sample included 766 participants. After adjusting for age and sex, impaired kidney function at baseline was not associated with a higher risk of all-cause dementia (hazard ratio [HR], 0.95; 95% CI, 0.69-1.29), AD (HR, 0.94; 95% CI, 0.55-1.63), or vascular dementia diagnosis (HR, 1.06; 95% CI, 0.65-1.70) within 17 years. In the cross-sectional analysis, after adjusting for age and sex, impaired kidney function was significantly associated with NfL and p-tau181 levels in blood (NfL: β = 0.47 and P < .001; p-tau181: β = 0.21 and P = .003). After adjusting for age and sex, significant associations with GFAP levels were evident only among men (men: β = 0.31 and P = .006; women: β = -0.12 and P = .11).In this population-based study of community-dwelling adults, reduced kidney function was associated with increased levels of dementia-related blood biomarkers but not increased dementia risk. Kidney function might influence the accuracy of dementia-related blood biomarkers and should be considered in clinical translation.
000212457 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000212457 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000212457 7001_ $$aBeyer, Léon$$b1
000212457 7001_ $$0P:(DE-He78)b09508a4c4afe85c57dd131eefa689ea$$aTrares, Kira$$b2$$udkfz
000212457 7001_ $$aPerna, Laura$$b3
000212457 7001_ $$aRujescu, Dan$$b4
000212457 7001_ $$aHolleczek, Bernd$$b5
000212457 7001_ $$aBeyreuther, Konrad$$b6
000212457 7001_ $$aGerwert, Klaus$$b7
000212457 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b8$$udkfz
000212457 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b9$$eLast author$$udkfz
000212457 773__ $$0PERI:(DE-600)2931249-8$$a10.1001/jamanetworkopen.2022.52387$$gVol. 6, no. 1, p. e2252387 -$$n1$$pe2252387 -$$tJAMA network open$$v6$$x2574-3805$$y2023
000212457 909CO $$ooai:inrepo02.dkfz.de:212457$$pVDB
000212457 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)104fae0755c89365b7ae32238b3f1f52$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000212457 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b09508a4c4afe85c57dd131eefa689ea$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000212457 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000212457 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000212457 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000212457 9141_ $$y2023
000212457 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-10-18T13:36:16Z
000212457 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-10-18T13:36:16Z
000212457 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-16
000212457 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-16
000212457 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-16
000212457 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-16
000212457 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJAMA NETW OPEN : 2022$$d2023-10-27
000212457 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-27
000212457 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-27
000212457 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2021-10-18T13:36:16Z
000212457 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-27
000212457 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-27
000212457 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-27
000212457 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJAMA NETW OPEN : 2022$$d2023-10-27
000212457 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000212457 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000212457 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000212457 980__ $$ajournal
000212457 980__ $$aVDB
000212457 980__ $$aI:(DE-He78)C070-20160331
000212457 980__ $$aUNRESTRICTED